quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:27:18·62d
INSIDERFiling
Organogenesis Holdings Inc. logo

Director Giacomin Jon L was granted 48,828 shares, increasing direct ownership by 25% to 241,026 units (SEC Form 4)

ORGO· Organogenesis Holdings Inc.
Health Care
Original source

Companies

  • ORGO
    Organogenesis Holdings Inc.
    Health Care

Recent analyst ratings

  • Jun 28UpdateLake Street$5.00
  • Feb 7UpdateCantor Fitzgerald$5.00
  • Jun 15UpdateMorgan Stanley$5.00
  • May 24UpdateBTIG Research$10.00
  • Nov 10UpdateBTIG Research-
  • Aug 10UpdateOppenheimer-

Related

  • PR17d
    Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
  • PR17d
    Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
  • PR18d
    Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
  • INSIDER43d
    Director Leibowitz Arthur S bought $13,405 worth of shares (5,000 units at $2.68), increasing direct ownership by 2% to 291,014 units (SEC Form 4)
  • INSIDER43d
    Director Driscoll Michael Joseph bought $26,688 worth of shares (10,000 units at $2.67), increasing direct ownership by 5% to 225,707 units (SEC Form 4)
  • INSIDER51d
    Vice President, Strategy Cavorsi Robert covered exercise/tax liability with 700 shares, decreasing direct ownership by 0.25% to 275,524 units (SEC Form 4)
  • SEC56d
    SEC Form 10-K filed by Organogenesis Holdings Inc.
  • SEC56d
    Organogenesis Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022